PMID- 35188403
OWN - NLM
STAT- MEDLINE
DCOM- 20220609
LR  - 20220615
IS  - 0028-2685 (Print)
IS  - 0028-2685 (Linking)
VI  - 69
IP  - 3
DP  - 2022 May
TI  - Elevation of miR-125b-5p is related to improved prognosis in laryngeal squamous 
      cell carcinoma and inhibits the malignancy and glycometabolic disorder by 
      targeting MAP3K9.
PG  - 550-559
LID - 211027N1532 [pii]
LID - 10.4149/neo_2022_211027N1532 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is the most common malignant tumor in 
      the head and neck cancer, with a poor prognosis. As we know, microRNAs (miRNAs) 
      play a vital role in the initiation and development of various cancers including 
      LSCC. In this study, we explored the role of miR-125b-5p and its downstream 
      regulatory pathway in LSCC. Our data demonstrated that miR-125b-5p expression was 
      significantly downregulated in LSCC tissues and cells. LSCC patients with high 
      expression of miR-125b-5p had higher overall survival (OS) and were closely 
      related to the clinical stage. Overexpression of miR-125b-5p impaired viability 
      and glycolysis, and facilitated apoptosis in LSCC cells. And miR-125b-5p 
      silencing had the opposite effects. Bioinformatics website predicted that MAP3K9 
      was one of the potential target genes of miR-125b-5p. Cell experiments 
      demonstrated that miR-125b-5p repressed the MAP3K9 levels by directly targeting 
      MAP3K9. Additionally, the negative correlation between miR-125b-5p and MAP3K9 was 
      validated in LSCC tissues. Overexpression of MAP3K9 attenuated the inhibitory 
      effect of miR-125b-5p on viability and glycolysis, and the pro-apoptosis effect 
      of miR-125b-5p in LSCC cells. Furthermore, in vivo experiments demonstrated that 
      tumor growth was hampered in AMC-HN-8 cells transfected with miR-125b-5p mimic. 
      In contrast, the knockdown of miR-125b-5p reduced tumor growth in vivo. 
      Meanwhile, the in vivo immunohistochemistry and TUNEL assays suggested that the 
      miR-125b-5p overexpression restrained cell proliferation and promoted apoptosis 
      via targeting MAP3K9. Overall, these above results suggested that miR-125b-5p 
      suppressed proliferation and glycolysis, and promoted apoptosis by directly 
      targeting MAP3K9 in LSCC cells. Thus, miR-125b-5p acts as a tumor suppressor 
      miRNA and the miR-125b-5p/MAP3K9 axis may be a promising candidate for LSCC 
      treatment.
FAU - Chen, Fu
AU  - Chen F
AD  - Department of Radiation Oncology, Eye and ENT Hospital of Fudan University, 
      Shanghai, China.
FAU - Lao, Zheng
AU  - Lao Z
AD  - Radiotherapy Division, Department of Oral and Maxillofacial-Head and Neck 
      Oncology, Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 
      School of Medicine, Shanghai, China.
FAU - Zhang, Hai-Yan
AU  - Zhang HY
AD  - Department of Radiation Oncology, Eye and ENT Hospital of Fudan University, 
      Shanghai, China.
FAU - Wang, Jie
AU  - Wang J
AD  - Department of Radiation Oncology, Eye and ENT Hospital of Fudan University, 
      Shanghai, China.
FAU - Wang, Sheng-Zi
AU  - Wang SZ
AD  - Department of Radiation Oncology, Eye and ENT Hospital of Fudan University, 
      Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220222
PL  - Slovakia
TA  - Neoplasma
JT  - Neoplasma
JID - 0377266
RN  - 0 (MIRN125 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
RN  - EC 2.7.11.25 (MAP3K9 protein, human)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Humans
MH  - *Laryngeal Neoplasms/pathology
MH  - *MAP Kinase Kinase Kinases/genetics/metabolism
MH  - *MicroRNAs/biosynthesis/genetics/metabolism
MH  - Prognosis
MH  - *Squamous Cell Carcinoma of Head and Neck
EDAT- 2022/02/22 06:00
MHDA- 2022/06/10 06:00
CRDT- 2022/02/21 12:10
PHST- 2021/10/27 00:00 [received]
PHST- 2022/01/17 00:00 [accepted]
PHST- 2022/02/22 06:00 [pubmed]
PHST- 2022/06/10 06:00 [medline]
PHST- 2022/02/21 12:10 [entrez]
AID - 211027N1532 [pii]
AID - 10.4149/neo_2022_211027N1532 [doi]
PST - ppublish
SO  - Neoplasma. 2022 May;69(3):550-559. doi: 10.4149/neo_2022_211027N1532. Epub 2022 
      Feb 22.